BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of ...
The MarketWatch News Department was not involved in the creation of this content. METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial ...
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Spain’s Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National ...
Novocure (NASDAQ: NVCR) announced topline results today from its Phase 3 TRIDENT trial, which evaluated the initiation of Tumor Treating Fields (TTFields) therapy for newly diagnosed glioblastoma (GBM ...
The standard of care established in the early 2000s is, in most respects, still the standard of care today—a fact that ...
Tumor-Treating Fields Open the Door to Progress for Patients With Locally Advanced Pancreatic Cancer
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial In the article that ...
Novocure (NVCR) announced on Thursday that its cancer treatment device, Tumor Treating Fields (TTFields), reached the primary endpoint in its Phase 2 PANOVA-4 trial for patients with a certain form of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results